MA39247A1 - 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque - Google Patents
2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaqueInfo
- Publication number
- MA39247A1 MA39247A1 MA39247A MA39247A MA39247A1 MA 39247 A1 MA39247 A1 MA 39247A1 MA 39247 A MA39247 A MA 39247A MA 39247 A MA39247 A MA 39247A MA 39247 A1 MA39247 A1 MA 39247A1
- Authority
- MA
- Morocco
- Prior art keywords
- obesity
- treatment
- diabetes mellitus
- guanidinophenyl
- hyperlipidemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne un composé hétérocyclique fusionné ayant une action inhibitrice de l'entéropeptidase et une utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc.. Plus particulièrement, elle concerne un composé représenté par la formule suivante (i) : dans laquelle chaque symbole est tel que défini dans la description, ou un sel de celui-ci et l'utilisation du composé en tant que médicament pour le traitement ou la prophylaxie de l'obésité, du diabète sucré, etc..
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014025944 | 2014-02-13 | ||
PCT/JP2015/000640 WO2015122188A1 (fr) | 2014-02-13 | 2015-02-12 | Composé hétérocyclique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39247A1 true MA39247A1 (fr) | 2017-11-30 |
MA39247B1 MA39247B1 (fr) | 2018-04-30 |
Family
ID=52589730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39247A MA39247B1 (fr) | 2014-02-13 | 2015-02-12 | 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque |
Country Status (22)
Country | Link |
---|---|
US (2) | US9428470B2 (fr) |
EP (1) | EP3105228B1 (fr) |
JP (1) | JP6458054B2 (fr) |
KR (1) | KR20160113299A (fr) |
CN (1) | CN106170487A (fr) |
AR (1) | AR099399A1 (fr) |
AU (1) | AU2015216439A1 (fr) |
BR (1) | BR112016018548A2 (fr) |
CA (1) | CA2939675A1 (fr) |
CL (1) | CL2016002023A1 (fr) |
CR (1) | CR20160368A (fr) |
EA (1) | EA201691624A1 (fr) |
EC (1) | ECSP16067163A (fr) |
IL (1) | IL247018A0 (fr) |
MA (1) | MA39247B1 (fr) |
MX (1) | MX2016010561A (fr) |
PE (1) | PE20161396A1 (fr) |
PH (1) | PH12016501614A1 (fr) |
SG (1) | SG11201606176YA (fr) |
TW (1) | TW201609677A (fr) |
UY (1) | UY35995A (fr) |
WO (1) | WO2015122188A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105051008B (zh) | 2013-03-13 | 2018-05-29 | 武田药品工业株式会社 | 胍基苯甲酸酯化合物 |
RU2728790C2 (ru) | 2014-02-10 | 2020-07-31 | Фред Хатчинсон Кансэр Рисёч Сентер | Лечение сердечного приступа и ишемического повреждения соединениями галогена |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
BR112016018555B1 (pt) | 2014-02-13 | 2024-01-23 | Incyte Holdings Corporation | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 |
SG11201606689VA (en) | 2014-02-13 | 2016-09-29 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9428470B2 (en) * | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015123437A1 (fr) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines en tant qu'inhibiteurs de lsd1 |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
WO2016007731A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1 |
JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
WO2016158788A1 (fr) * | 2015-03-27 | 2016-10-06 | 武田薬品工業株式会社 | Composé hétérocyclique fusionné |
US9944647B2 (en) | 2015-04-03 | 2018-04-17 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
US10329255B2 (en) | 2015-08-12 | 2019-06-25 | Incyte Corporation | Salts of an LSD1 inhibitor |
BR112020008676A2 (pt) | 2017-11-02 | 2020-10-27 | Ube Industries, Ltd. | composto, e, composição farmacêutica. |
EP3778577B1 (fr) | 2018-05-09 | 2023-08-30 | Lg Chem, Ltd. | Nouveau composé présentant une activité inhibitrice de l'entéropeptidase |
AR116019A1 (es) * | 2018-08-27 | 2021-03-25 | Scohia Pharma Inc | Derivados de guanidinobenzoilo como inhibidores de enteropeptidasa |
WO2020047198A1 (fr) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Sels d'un inhibiteur de lsd1 et leurs procédés de préparation |
WO2021013742A1 (fr) | 2019-07-19 | 2021-01-28 | Janssen Pharmaceutica Nv | Dérivés de [1,2,4]triazolo[1,5-a]pyridinyle 5,8-disubstitués et d'imidazo[1,2-a]pyridine 5,8-disubstitués utiles en tant qu'inhibiteurs de l'entéropeptidase |
JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
CA3160144A1 (fr) * | 2019-11-04 | 2021-07-08 | Faraday Pharmaceuticals, Inc. | Utilisation de composes d'iodure pour le traitement et la prevention d'une cardiotoxicite et d'une cachexie associees a une chimiotherapie |
WO2021166899A1 (fr) * | 2020-02-17 | 2021-08-26 | 宇部興産株式会社 | Médicament contenant un inhibiteur de protéase gastrique destiné à être utilisé en association avec un mimétique d'incrétine |
CN111803652B (zh) * | 2020-08-04 | 2021-09-14 | 南通康是美生物科技有限公司 | 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
EP0673924A4 (fr) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | Derive d'acide proprionique. |
JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
EP0862562B1 (fr) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Composes de benzoxazepine, leur production et leur utilisation en tant qu'agent d'abaissement des niveaux de lipides |
JPH09124571A (ja) | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
KR20000005312A (ko) | 1996-04-10 | 2000-01-25 | 오노 야꾸힝 고교 가부시키가이샤 | 트립타아제 억제제 및 신규 구아니디노 유도체 |
JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターd阻害剤 |
JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規4h−3,1−ベンゾオキサジン−4−オン誘導体 |
JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
WO2002006234A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, procede de production et utilisation de ces derives |
AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
CA2527691C (fr) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Compose cyclique condense |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
WO2005063725A1 (fr) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | Derives d'acide phenylpropanoique |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
EP1815865A4 (fr) | 2004-11-08 | 2010-08-25 | Ono Pharmaceutical Co | Agent thérapeutique contre le diabète comprenant un composé inhibiteur de protéase |
EP1843819A2 (fr) | 2004-11-15 | 2007-10-17 | Obe Therapy Biotechnology S.A.S. | Procedes de reduction de la graisse corporelle |
EP1811865B1 (fr) | 2004-11-26 | 2008-07-16 | N.V. Nutricia | Aliment pour nourrisson contenant un inhibiteur de protease |
US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
EP1911738A4 (fr) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | Composé de l acide phénoxyalkanoique |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
US20080009530A1 (en) | 2005-08-10 | 2008-01-10 | Hidenori Abe | Therapeutic Agent for Diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
EP1973405A4 (fr) | 2006-01-12 | 2011-06-01 | Merck Sharp & Dohme | Derives d'hydroxyalkymarylamide |
EP2743268A3 (fr) | 2006-06-27 | 2014-10-08 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
EP2298772A1 (fr) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condenseé |
US7652133B2 (en) | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
WO2008099794A1 (fr) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Composés à cycles fusionnés utiles en tant qu'agonistes partiels de ppar-gamma |
EP2149550A4 (fr) | 2007-04-27 | 2010-08-11 | Takeda Pharmaceutical | Composé hétérocyclique à cinq chaînons à teneur en azote |
EP2157859A4 (fr) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | Composés d'indazole permettant d'activer la glucokinase |
PT2225261E (pt) | 2007-12-03 | 2016-06-09 | Obe Therapy Biotechnology | Inibidores boropeptídicos de enteropeptidase e suas utilizações no tratamento de obesidade, excesso de peso e/ou doenças associadas com um metabolismo anormal da gordura |
ES2532201T3 (es) | 2009-12-07 | 2015-03-25 | Ajinomoto Co., Inc. | Derivado de éster de ácido heteroarilcarboxílico |
JP5959116B2 (ja) | 2011-06-07 | 2016-08-02 | Eaファーマ株式会社 | ヘテロ環カルボン酸エステル誘導体 |
MX362948B (es) | 2011-09-15 | 2019-02-27 | Astellas Pharma Inc | Compuesto del ácido guanidinobenzoico. |
EP2800579B1 (fr) | 2012-01-03 | 2017-08-30 | Oramed Ltd. | Capsules comprenant des compositions liquides contenant une combinaison d'agents thérapeutiques pour le traitement du diabète |
US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
EP4215205A1 (fr) | 2013-01-03 | 2023-07-26 | Oramed Ltd. | Procédés et compositions pour le traitement de nafld, de la stéatose hépatique et de ses séquelles |
JP6374889B2 (ja) | 2013-03-08 | 2018-08-15 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法 |
CN105051008B (zh) | 2013-03-13 | 2018-05-29 | 武田药品工业株式会社 | 胍基苯甲酸酯化合物 |
LT3010910T (lt) | 2013-06-21 | 2020-03-10 | MyoKardia, Inc. | Pirimidindiono junginiai, skirti širdies ligoms |
WO2015036792A1 (fr) | 2013-09-16 | 2015-03-19 | Astrazeneca Ab | Nanoparticules polymères thérapeutiques et leurs procédés de fabrication et d'utilisation |
BR112016018555B1 (pt) | 2014-02-13 | 2024-01-23 | Incyte Holdings Corporation | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 |
US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
SG11201606689VA (en) | 2014-02-13 | 2016-09-29 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2015
- 2015-02-11 US US14/619,464 patent/US9428470B2/en not_active Expired - Fee Related
- 2015-02-12 JP JP2016569124A patent/JP6458054B2/ja not_active Expired - Fee Related
- 2015-02-12 CA CA2939675A patent/CA2939675A1/fr not_active Abandoned
- 2015-02-12 BR BR112016018548A patent/BR112016018548A2/pt not_active Application Discontinuation
- 2015-02-12 MA MA39247A patent/MA39247B1/fr unknown
- 2015-02-12 SG SG11201606176YA patent/SG11201606176YA/en unknown
- 2015-02-12 KR KR1020167024873A patent/KR20160113299A/ko not_active Application Discontinuation
- 2015-02-12 PE PE2016001481A patent/PE20161396A1/es not_active Application Discontinuation
- 2015-02-12 EP EP15706547.5A patent/EP3105228B1/fr active Active
- 2015-02-12 TW TW104104692A patent/TW201609677A/zh unknown
- 2015-02-12 AU AU2015216439A patent/AU2015216439A1/en not_active Abandoned
- 2015-02-12 EA EA201691624A patent/EA201691624A1/ru unknown
- 2015-02-12 AR ARP150100410A patent/AR099399A1/es unknown
- 2015-02-12 CN CN201580019434.9A patent/CN106170487A/zh active Pending
- 2015-02-12 MX MX2016010561A patent/MX2016010561A/es unknown
- 2015-02-12 CR CR20160368A patent/CR20160368A/es unknown
- 2015-02-12 UY UY0001035995A patent/UY35995A/es not_active Application Discontinuation
- 2015-02-12 US US15/117,539 patent/US10023544B2/en not_active Expired - Fee Related
- 2015-02-12 WO PCT/JP2015/000640 patent/WO2015122188A1/fr active Application Filing
-
2016
- 2016-07-31 IL IL247018A patent/IL247018A0/en unknown
- 2016-08-10 CL CL2016002023A patent/CL2016002023A1/es unknown
- 2016-08-11 EC ECIEPI201667163A patent/ECSP16067163A/es unknown
- 2016-08-12 PH PH12016501614A patent/PH12016501614A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2939675A1 (fr) | 2015-08-20 |
SG11201606176YA (en) | 2016-08-30 |
PH12016501614A1 (en) | 2017-02-06 |
ECSP16067163A (es) | 2017-10-31 |
EP3105228A1 (fr) | 2016-12-21 |
AU2015216439A1 (en) | 2016-08-11 |
UY35995A (es) | 2015-08-31 |
CL2016002023A1 (es) | 2017-03-24 |
IL247018A0 (en) | 2016-09-29 |
US20160347724A1 (en) | 2016-12-01 |
PE20161396A1 (es) | 2017-01-10 |
BR112016018548A2 (pt) | 2019-01-15 |
KR20160113299A (ko) | 2016-09-28 |
CN106170487A (zh) | 2016-11-30 |
TW201609677A (zh) | 2016-03-16 |
US10023544B2 (en) | 2018-07-17 |
EP3105228B1 (fr) | 2018-09-26 |
MX2016010561A (es) | 2016-11-16 |
MA39247B1 (fr) | 2018-04-30 |
US9428470B2 (en) | 2016-08-30 |
US20150225354A1 (en) | 2015-08-13 |
CR20160368A (es) | 2016-12-01 |
JP2017505823A (ja) | 2017-02-23 |
EA201691624A1 (ru) | 2017-05-31 |
AR099399A1 (es) | 2016-07-20 |
JP6458054B2 (ja) | 2019-01-23 |
WO2015122188A1 (fr) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39247A1 (fr) | 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d'enteropeptidase utiles pour le traitement ou la prevention, par ex. L'obesite, le diabete sucre, les troubles de l'alimentation, l'hyperlipidemie, l'hypertension, l'insuffisance cardiaque | |
MA39246A1 (fr) | Composé hétérocyclique fusionné | |
MD3269370T2 (ro) | Compus pirimidinic condensat nou sau sare a acestuia | |
EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
MA35085B1 (fr) | Procede de traitement d'une nephropathie induite par les produits de contraste | |
ECSP20075270A (es) | Compuestos | |
MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
MA39688A (fr) | Composés hétéroaryle pour le traitement de maladies ophtalmiques | |
MA46337B1 (fr) | Composé de pyridine | |
MA39427B1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
MA38472A1 (fr) | Composé peptidique | |
MA34713B1 (fr) | Compose bicyclique | |
MA35623B1 (fr) | Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives | |
MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
MA40302A1 (fr) | Dérivés de carbazole | |
MX2019010085A (es) | Inhibidores de la glicosidasa de sulfoximina. | |
EA201992306A1 (ru) | Ингибиторы ip6k | |
MA32283B1 (fr) | Composes cycliques condenses et utilisation de ceux-ci | |
MA43913A (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA38358A1 (fr) | Formulations de composés organiques | |
MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci | |
MA43231B1 (fr) | Bloqueur des canaux sodiques | |
MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
MA45855B1 (fr) | Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide |